AbbVie confirmed that it will present the results of a Phase I clinical trial of ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal Antibody-drug Conjugate (ADC), for the treatment of glioblastoma multiform at the upcoming 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 3, in Chicago, Il.
“Our clinical trial program underscores our commitment to developing innovative therapies that improve on current treatment options and create better outcomes for patients,” noted Gary Gordon, M.D., vice president, Oncology Development, AbbVie. “We have made substantial progress advancing our lead investigational compounds into Phase III testing and remain dedicated to the continued development of the other compounds in our oncology pipeline.”
ABT-414 is being evaluated for the treatment of patients with various cancer and tumor types. As an ADC, ABT-414 is designed to be stable in the bloodstream and only release the potent cytotoxic agent once inside targeted cancer cells, thereby reducing the toxic side effects of traditional chemotherapy while enhancing anti-tumor activity. Being developed by AbbVie researchers, ABT-414 is currently being investigated in Phase I/II for the treatment of glioblastoma multiforme, the most common and most aggressive malignant primary brain tumor. ABT-414 is also in clinical trials for the treatment of patients with squamous cell tumors.
Published in: AbbVie Website